E3 PreliminaryPreliminaryPEM not requiredMechanisticPeer-reviewedMachine draft
Effect of Hochu-ekki-to (TJ-41), a Japanese Herbal Medicine, on Daily Activity in a Murine Model of Chronic Fatigue Syndrome.
Wang, Xin Q, Takahashi, Takashi, Zhu, Shi-Jie et al. · Evidence-based complementary and alternative medicine : eCAM · 2004 · DOI
Quick Summary
Researchers tested a Japanese herbal medicine called Hochu-ekki-to (TJ-41) in mice with an experimentally induced condition similar to ME/CFS. Mice treated with the herb showed better activity levels and survived longer than untreated mice, suggesting the herb may help reduce activity loss associated with chronic fatigue-like conditions.
Why It Matters
Understanding mechanisms by which herbal medicines may mitigate activity loss in CFS-like conditions could inform both conventional and complementary treatment approaches. This work bridges traditional medicine and contemporary immunology, potentially identifying biomarkers and pathways relevant to human ME/CFS.
Observed Findings
- Daily running activity was significantly higher in TJ-41-treated mice compared to untreated controls.
- Two mice in the untreated group died 2 days after the second BA injection; no deaths occurred in the treated group.
- Spleen weight and spleen-to-body-weight ratio were significantly lower in treated mice.
- Splenic IL-10 mRNA expression was suppressed in mice receiving TJ-41.
- No significant differences in body weight between groups were reported.
Inferred Conclusions
- Hochu-ekki-to possesses an inhibitory effect on marked decreases in running activity following BA antigen exposure.
- The herbal medicine may confer survival benefits in this model through modulation of immune responses.
- IL-10 suppression may represent a mechanism by which TJ-41 attenuates fatigue-like symptoms.
Remaining Questions
- Does TJ-41 produce similar immunological and activity benefits in human ME/CFS patients?
- Which active constituent(s) of TJ-41 are responsible for the observed effects?
- What is the optimal dose and duration of TJ-41 treatment, and are there dose-dependent relationships?
What This Study Does Not Prove
This animal model study does not prove TJ-41 is safe or effective in human ME/CFS patients. BA-induced fatigue in mice may not fully recapitulate human ME/CFS pathophysiology, and findings cannot be directly translated to clinical use without further mechanistic and clinical validation. The study does not establish which component(s) of TJ-41 are active or clarify whether suppressed IL-10 is causally related to improved activity.
Tags
Symptom:Fatigue
Biomarker:CytokinesGene Expression
Phenotype:Infection-Triggered
Method Flag:PEM Not DefinedWeak Case DefinitionSmall SampleExploratory Only
Metadata
- DOI
- 10.1093/ecam/neh020
- PMID
- 15480446
- Review status
- Machine draft
- Evidence level
- Early hypothesis, preprint, editorial, or weak support
- Last updated
- 8 April 2026
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →